sotorasib and Carcinoma--Pancreatic-Ductal

sotorasib has been researched along with Carcinoma--Pancreatic-Ductal* in 1 studies

Other Studies

1 other study(ies) available for sotorasib and Carcinoma--Pancreatic-Ductal

Article	Year
Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer. Cancer discovery, 2022, 04-01, Volume: 12, Issue:4 The KRASG12C inhibitor sotorasib was associated with a 21.1% objective response rate and an 84.2% disease control rate among patients who had already received at least one therapy for pancreatic ductal adenocarcinoma. These data come from the phase I/II CodeBreaK100 trial. Topics: Carcinoma, Pancreatic Ductal; Humans; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines	2022

Article

Year

Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer.

Cancer discovery, 2022, 04-01, Volume: 12, Issue:4

The KRASG12C inhibitor sotorasib was associated with a 21.1% objective response rate and an 84.2% disease control rate among patients who had already received at least one therapy for pancreatic ductal adenocarcinoma. These data come from the phase I/II CodeBreaK100 trial.

Topics: Carcinoma, Pancreatic Ductal; Humans; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines

2022